Innovent will push VANFLYTA deeper into China’s AML market as Daiichi Sankyo sup

Turning Headlines into Foresight.

Innovent and Daiichi Sankyo strike China deal for VANFLYTA commercialization

pharma·Short term·▼ -4%

80%

Innovent will push VANFLYTA deeper into China’s AML market as Daiichi Sankyo supplies the drug.

This is a meaningful China oncology commercialization move for both companies and a direct access story for a high-risk AML population.

AI reasoning

This is a meaningful China oncology commercialization move for both companies and a direct access story for a high-risk AML population.

Curated summary

Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement for VANFLYTA commercialization in Mainland China. Daiichi Sankyo will handle development, manufacturing and supply, while Innovent gets sole commercialization rights and market promotion. VANFLYTA, or quizartinib, was approved in China in June 2026 for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.